Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2024-06-04 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and the purpose of the repurchase (employee stock ownership plan or equity incentives). It references prior announcements about the repurchase plan and complies with regulatory disclosure requirements. The document length is 1629 characters, which is relatively short and focused solely on the share buyback progress, not a full financial report or earnings release. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares.
2024-06-04 Chinese
美迪西：关于股东部分股份被司法冻结的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the judicial freezing of a shareholder's shares. It details the shareholder's name, the number of shares frozen, the freezing authority, and the impact on the company. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of management or board changes. The document is a regulatory announcement about a shareholder's share status, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a specific regulatory disclosure about share freezing, which is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other categories.
2024-06-04 Chinese
美迪西：关于以集中竞价交易方式首次回购公司股份暨回购进展的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shanghai Medicilon Inc. regarding the company's first share repurchase via centralized bidding. It details the repurchase plan, implementation period, amount, purpose (employee stock ownership plan or equity incentive), progress of the repurchase, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but reports on the company's share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares.
2024-05-30 Chinese
美迪西：2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2023 Annual General Meeting (AGM) of Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including the 2023 annual report, financial statements, director and supervisor reports, remuneration plans, and changes to company governance documents. The document is not the annual report itself but the official announcement of the voting results and resolutions from the AGM. The length is under 5,000 characters and it focuses on the meeting outcomes and voting tallies, which fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-05-17 Chinese
美迪西：关于召开2023年度暨2024年第一季度业绩说明会的公告
Regulatory Filings Classification · 90% confidence The document is an announcement about the scheduling of an investor earnings explanation meeting (业绩说明会) for the 2023 annual and 2024 first quarter results. It provides details on the meeting time, location, participants, and how investors can participate and ask questions. It references that the 2023 annual report and 2024 Q1 report have already been published. The document itself does not contain financial data or the actual report but is an announcement of the upcoming earnings call/meeting. Therefore, it is not the earnings release (ER) or the interim report (IR) itself, but an announcement related to the earnings call. The best fitting category is Call Transcript (CT) since it is about the earnings explanation meeting, but since this is only an announcement of the meeting and not the transcript, it is more appropriate to classify it as Regulatory Filings (RNS) as a general regulatory announcement about the earnings call meeting. However, given the definitions, the document is an announcement of an earnings explanation meeting, which is closest to a Call Transcript (CT) announcement, but since it is not the transcript itself, and not a report publication announcement (RPA) either, the fallback category Regulatory Filings (RNS) is most appropriate here.
2024-05-17 Chinese
北京安理（上海）律师事务所关于上海美迪西生物医药股份有限公司2023年年度股东大会的法律意见书
Regulatory Filings
2024-05-17 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.